AbbVie Inc. (ABBV)
NYSE: ABBV · Real-Time Price · USD
247.97
+1.93 (0.78%)
At close: Aug 10, 2026, 4:00 PM EDT
247.74
-0.23 (-0.09%)
Pre-market: Aug 11, 2026, 7:42 AM EDT
AbbVie Revenue
AbbVie had revenue of $16.99B in the quarter ending June 30, 2026, with 10.16% growth. This brings the company's revenue in the last twelve months to $64.39B, up 10.39% year-over-year. In the year 2025, AbbVie had annual revenue of $61.16B with 8.57% growth.
Revenue (ttm)
$64.39B
Revenue Growth
+10.39%
P/S Ratio
6.81
Revenue / Employee
$1,129,579
Employees
57,000
Market Cap
438.19B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 61.16B | 4.83B | 8.57% |
| Dec 31, 2024 | 56.33B | 2.02B | 3.71% |
| Dec 31, 2023 | 54.32B | -3.74B | -6.44% |
| Dec 31, 2022 | 58.05B | 1.86B | 3.30% |
| Dec 31, 2021 | 56.20B | 10.39B | 22.69% |
| Dec 31, 2020 | 45.80B | 12.54B | 37.69% |
| Dec 31, 2019 | 33.27B | 513.00M | 1.57% |
| Dec 31, 2018 | 32.75B | 4.54B | 16.08% |
| Dec 31, 2017 | 28.22B | 2.58B | 10.06% |
| Dec 31, 2016 | 25.64B | 2.78B | 12.16% |
| Dec 31, 2015 | 22.86B | 2.90B | 14.52% |
| Dec 31, 2014 | 19.96B | 1.17B | 6.23% |
| Dec 31, 2013 | 18.79B | 410.00M | 2.23% |
| Dec 31, 2012 | 18.38B | 936.00M | 5.37% |
| Dec 31, 2011 | 17.44B | 1.81B | 11.55% |
| Dec 31, 2010 | 15.64B | 1.42B | 10.02% |
| Dec 31, 2009 | 14.21B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Johnson & Johnson | 97.93B |
| Eli Lilly and Company | 79.67B |
| Merck & Co. | 66.57B |
| Pfizer | 63.70B |
| AstraZeneca | 61.37B |
| Novartis AG | 56.69B |
| Novo Nordisk | 50.34B |
| Bristol-Myers Squibb Company | 49.19B |
ABBV News
- 23 hours ago - AbbVie price target raised to $260 from $246 at Evercore ISI - TheFly
- 5 days ago - AbbVie upgraded to Buy from Hold at Erste Group - TheFly
- 6 days ago - AbbVie’s Botox Cosmetic sBLA for masseter muscle prominence accepted by FDA - TheFly
- 6 days ago - AbbVie’s Allergan Aesthetics receives FDA approval of sBLA for Botox Cosmetic - TheFly
- 6 days ago - Allergan Aesthetics Announces U.S. FDA Acceptance of Supplemental Biologics License Application for BOTOX® Cosmetic for Masseter Muscle Prominence - PRNewsWire
- 7 days ago - AbbVie price target raised to $288 from $261 at Guggenheim - TheFly
- 7 days ago - AbbVie price target raised to $285 from $265 at Cantor Fitzgerald - TheFly
- 7 days ago - AbbVie price target raised to $296 from $278 at Morgan Stanley - TheFly